Skip to main content
SpringerLink
Log in

Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: A single-blind randomized study

  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Schizophrenia is a devastating psychiatric disorder. Clozapine has long been the gold standard for treatment of patients with treatment-resistant schizophrenia; however, some patients are only partially responsive to clozapine treatment. Augmentation of clozapine treatment might enhance its effectiveness in partial responders, but only a few studies have investigated possible augmentation strategies. This study compared the effectiveness and tolerability of the combination of amisulpride and clozapine with the combination of quetiapine and clozapine in patients who were only partially responsive to clozapine monotherapy. Fifty-six treatment-resistant patients who were partially responsive to clozapine were randomly assigned to receive amisulpride or quetiapine along with an ongoing stable dose of clozapine. Fifty patients completed the study. Patients were evaluated at baseline and at the first, third, sixth, and eighth weeks. Efficacy measures consisted of the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Negative Symptoms (SANS), the Scale for the Assessment of Positive Symptoms (SAPS), and the Clinical Global Impression (CGI) scale. Tolerability and adverse effects were assessed with the Udvalg for Kliniske Undersogelser (UKU) Side Effect Rating Scale and the Simpson Angus Scale (SAS). A substantial improvement occurred in both groups by the end of the eighth week; however, the improvement associated with amisulpride was significantly greater than that seen with quetiapine. This difference was noted as early as the third week of follow-up in terms of CGI scores, and by the sixth week with regard to BPRS, SANS, and SAPS scores. Both drugs were well tolerated, as measured by UKU and SAS. Improvement favoring clozapine+amisulpride could be attributed to the selective D2/D3 binding property of amisulpride, which had an additional effect in improving symptoms of schizophrenia. The authors concluded that amisulpride seems to be effective and well tolerated for augmentation purposes in clozapine-resistant patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Essock SM, Hargreaves WA. Clozapine eligibility among state hospital patients.Schizophr Bull. 1996;22:15–25.

    PubMed  CAS  Google Scholar 

  2. Barnes TRE, Buckley P, Schultz SC. Treatment resistant schizophrenia. In: Hirsch SR, Weinberger D, eds.Schizophrenia. Oxford, Mass: Blackwell Science; 2003:489–517.

    Chapter  Google Scholar 

  3. Taner E, Cosar B, Isik E. The effects of the changes in symptoms of schizophrenia over functioning: two years of clozapine follow-up study [in Turkish].Psych Turkey. 2002;4:84–91.

    Google Scholar 

  4. McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuroleptic in acute schizophrenia: a controlled study of the neuroleptic threshold and higher haloperidol dose.Arch Gen Psychiatry. 1991;48:739–745.

    PubMed  CAS  Google Scholar 

  5. Kane JM. The current status of neuroleptic therapy.J Clin Psychiatry. 1989;50:322–328.

    PubMed  CAS  Google Scholar 

  6. Kane JM. Clinical efficacy of clozapine in treatment refractory schizophrenia: an overview.Br J Psychiatry Suppl. 1992;17:41–45.

    PubMed  Google Scholar 

  7. Conley RR, Buchanan RW. Evaluation of treatment-resistant schizophrenia.Schizophr Bull. 1997;23:663–674.

    PubMed  CAS  Google Scholar 

  8. Conley R, Kelly DL. Management of treatment resistance in schizophrenia.Biol Psychiatry. 2001; 50:898–911.

    Article  PubMed  CAS  Google Scholar 

  9. Meltzer HY. The role of serotonin in antipsychotic drug action.Neuropsychopharmacology. 1999; 21:106–115.

    Google Scholar 

  10. Buckley A, Miller J, Olsen D, Garver DD, Csernansky J. When symptoms persist: clozapine augmentation strategies.Schizophr Bull. 2001;27:615–628.

    PubMed  CAS  Google Scholar 

  11. Chong SA, Remington G. Clozapine augmentation: safety and efficacy.Schizophr Bull. 2000; 26:421–440.

    PubMed  CAS  Google Scholar 

  12. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia: a review of efficacy and risks of current combinations.Acta Psychiatr Scand. 2002;106:323–330.

    Article  PubMed  CAS  Google Scholar 

  13. Buchanan RW, Kirkpatrick B, Bryant N, Ball P, Breier A. Fluoxetine augmentation of clozapine treatment in patients with schizophrenia.Am J Psychiatry. 1996;153:1625–1627.

    PubMed  CAS  Google Scholar 

  14. Silver H, Kushnir M, Kaplan A. Fluvoxamine augmentation in clozapine-resistant schizophrenia: an open pilot study.Biol Psychiatry. 1996;40:671–674.

    Article  PubMed  CAS  Google Scholar 

  15. Small JG, Klapper MH, Malloy FW, Steadman TM. Tolerability and efficacy of clozapine combined with lithium in schizophrenia and schizoaffective disorder.J Clin Psychopharmacol. 2003;23:223–228.

    Article  PubMed  CAS  Google Scholar 

  16. Tiihonen J, Hallikainen T, Ryynanen OP, et al. Lamotrigine in treatment-resistant schizophrenia: a randomized placebo-controlled crossover trial.Biol Psychiatry. 2003;54:1241–1248.

    Article  PubMed  CAS  Google Scholar 

  17. Evins AE, Fitzgerald SM, Wine L, Rosselli R, Goff DC. Placebo-controlled trial of glycine added to clozapine in schizophrenia.Am J Psychiatry. 2000;157:826–828.

    Article  PubMed  CAS  Google Scholar 

  18. Carpenter WT, Breier A, Buchanan RW, Kirkpatrick B, Shepard P, Weiner E. Mazindol treatment of negative symptoms.Neuropsychopharmacology. 2000;23:365–374.

    Article  PubMed  CAS  Google Scholar 

  19. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine: a double-blind, placebo-controlled study.Br J Psychiatry. 1997; 171:569–573.

    Article  PubMed  CAS  Google Scholar 

  20. Anil AEY, Kivircik BBA, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety.J Clin Psychiatry. 2005;66:63–72.

    Article  Google Scholar 

  21. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial.Am J Psychiatry. 2005;162:130–136.

    Article  PubMed  Google Scholar 

  22. Henderson DC, Goff DC. Risperidone as an adjunct to clozapine therapy in chronic schizophrenics.J Clin Psychiatry. 1996;57:395–397.

    PubMed  CAS  Google Scholar 

  23. Scatton B, Claustre Y, Cudennec A, et al. Amisulpride: from animal pharmacology to therapeutic action.Int Clin Psychopharmacol. 1997;12(suppl 2):29–36.

    Article  Google Scholar 

  24. Leucht S. Amisulpride, a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.Int J Neuropsychopharmacol. 2004;7(suppl 1): 15–20.

    Article  CAS  Google Scholar 

  25. Munro J, Matthiasson P, Osborne S, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine.Acta Psychiatr Scand. 2004;110:292–298.

    Article  PubMed  CAS  Google Scholar 

  26. Agelink MW, Kavuk I, Ak I. Clozapine with amisulpride for refractory schizophrenia.Am J Psychiatry. 2004;161:924–925.

    Article  PubMed  Google Scholar 

  27. Zink M, Knopf U, Henn FA, et al. Combination of clozapine and amisulpride in treatmentresistant schizophrenia—case reports and review of the literature.Pharmacopsychiatry. 2004;37: 26–31.

    Article  PubMed  CAS  Google Scholar 

  28. American Psychiatric Association.Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994.

    Google Scholar 

  29. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale.Psychol Rep. 1962;10:799–812.

    Article  Google Scholar 

  30. Woerner MG, Mennuzza S, Kane JM. Anchoring the BPRS-A: an aid to improved reliability.Psychopharmacol Bull. 1988;24:112–117.

    PubMed  CAS  Google Scholar 

  31. Andreasen NC. Methods for assessing positive and negative symptoms.Mod Probl Pharmacopsychiatry. 1990;24:73–88.

    PubMed  CAS  Google Scholar 

  32. Guy W, ed.ECDEU Assessment Manual for Psychopharmacology. Publication no. ADM 76-338. Washington, DC: US Department of Health, Education, and Welfare; 1976:218–222.

    Google Scholar 

  33. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and cross-sectional study of side effects in neuroleptic-treated patients.Acta Psychiatr Scand Suppl. 1987;334:1–100.

    Article  PubMed  CAS  Google Scholar 

  34. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects.Acta Psychiatr Scand Suppl. 1970;212:11–19.

    Article  PubMed  CAS  Google Scholar 

  35. Isik E. Equivalent doses of antipsychotic drugs. In: Isik E, ed.Current Schizophrenia. Norwich, England: Format Publishing; 2006;378–380.

    Google Scholar 

  36. Henderson DC, Kunkel L, Nguyen DD, et al. An explanatory open label trial of aripiprazole as an adjuvant to clozapine therapy in chronic schizophrenia.Acta Psychiatr Scand. 2006;113: 142–147.

    Article  PubMed  CAS  Google Scholar 

  37. Stern RG, Schmeidler J, Davidson M. Limitations of controlled augmentation trials in schizophrenia.Biol Psychiatry. 1997;42:138–143.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, Gazi University Faculty of Medicine, Besevler, Ankara, Turkey

    Yasin Genç MD, Ender Taner MD & Selcuk Candansayar MD

Authors
  1. Yasin Genç MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ender Taner MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Selcuk Candansayar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ender Taner MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Genç, Y., Taner, E. & Candansayar, S. Comparison of clozapine-amisulpride and clozapine-quetiapine combinations for patients with schizophrenia who are partially responsive to clozapine: A single-blind randomized study. Adv Therapy 24, 1–13 (2007). https://doi.org/10.1007/BF02849987

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02849987

Keywords

Search

Navigation